title: Trial watch: Monoclonal antibodies in cancer therapy.
abstract: During the past 20 years, dozens-if not hundreds-of monoclonal antibodies have been developed and characterized for their capacity to mediate antineoplastic effects, either as they activate/enhance tumor-specific immune responses, either as they interrupt cancer cell-intrinsic signal transduction cascades, either as they specifically delivery toxins to malignant cells or as they block the tumor-stroma interaction. Such an intense research effort has lead to the approval by FDA of no less than 14 distinct molecules for use in humans affected by hematological or solid malignancies. In the inaugural issue ofOncoImmunology, we briefly described the scientific rationale behind the use of monoclonal antibodies in cancer therapy and discussed recent, ongoing clinical studies investigating the safety and efficacy of this approach in patients. Here, we summarize the latest developments in this exciting area of clinical research, focusing on high impact studies that have been published during the last 15 months and clinical trials launched in the same period to investigate the therapeutic profile of promising, yet hitherto investigational, monoclonal antibodies.
authors.affiliation: Institut Gustave Roussy; Villejuif, France ; Université Paris-Sud/Paris XI; Le Kremlin-Bicêtre, France ; INSERM; U848; Villejuif, France.
authors.forename: Erika
authors.initials: E
authors.lastname: Vacchelli
authors.forename: Alexander
authors.initials: A
authors.lastname: Eggermont
authors.forename: Jérôme
authors.initials: J
authors.lastname: Galon
authors.forename: Catherine
authors.initials: C
authors.lastname: Sautès-Fridman
authors.forename: Laurence
authors.initials: L
authors.lastname: Zitvogel
authors.forename: Guido
authors.initials: G
authors.lastname: Kroemer
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Galluzzi
keywords: bevacizumab; dalotuzumab; ipilimumab; nimotuzumab; ramucirumab; trastuzumab